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Abstract
Background: The outcomes from an antiretroviral treatment (ART) program within the public sector in Myanmar have not
been reported. This study documents retention and the risk factors for attrition in a large ART public health program in
Myanmar.
Methods: A retrospective analysis of a cohort of adult patients enrolled in the Integrated HIV Care (IHC) Program between
June 2005 and October 2011 and followed up until April 2012 is presented. The primary outcome was attrition (death or
loss-follow up); a total of 10,223 patients were included in the 5-year cumulative survival analysis. Overall 5,718 patients
were analyzed for the risk factors for attrition using both logistic regression and flexible parametric survival models.
Result: The mean age was 36 years, 61% of patients were male, and the median follow up was 13.7 months. Overall 8,564
(84%) patients were retained in ART program: 750 (7%) were lost to follow-up and 909 (9%) died. During the 3 years follow-
up, 1,542 attritions occurred over 17,524 person years at risk, giving an incidence density of 8.8% per year. The retention
rates of participants at 12, 24, 36, 48 and 60 months were 86, 82, 80, 77 and 74% respectively. In multivariate analysis, being
male, having high WHO staging, a low CD4 count, being anaemic or having low BMI at baseline were independent risk
factors for attrition; tuberculosis (TB) treatment at ART initiation, a prior ART course before program enrollment and literacy
were predictors for retention in the program.
Conclusion: High retention rate of IHC program was documented within the public sector in Myanmar. Early diagnosis of
HIV, nutritional support, proper investigation and treatment for patients with low CD4 counts and for those presenting with
anaemia are crucial issues towards improvement of HIV program outcomes in resource-limited settings.
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Introduction
HIV epidemiology and ART coverage in Myanmar
Myanmar has a concentrated HIV epidemic and the global
HIV prevalence in adults has been estimated at 0.53% in a recent
modelling study [1]. In the same study, the HIV prevalence in
high risk groups has been estimated at 9.6, 7.8 and 21.9% in
female sex workers (FSW), men who have sex with men (MSM)
and injecting drug users (IDU), respectively [1].
There has been a very significant increase in the number of
patients receiving ART worldwide, and by the end of 2011, it had
reached 20 times the 2003 levels [2]. ART coverage in the Asia-
Pacific region increased from 52% in 2009 to 56% in 2011 [3]. By
the end of 2011, 40,128 people were receiving ART in Myanmar,
which was double the number observed in 2009 [1]. By the end of
2012, 34,733 (65%) patients on ART were followed in the private
sector (international NGOs) and 18,976 (35%) patients in the
public sector. As per the Asia Epidemic Model (AEM) 2010–2015,
the total numbers of people in need of ART in 2013, 2014 and
2015 are estimated at 125,043; 124,286 and 123,915 people
respectively. With extended support from the Global Fund against
AIDS, Tuberculosis and Malaria for a four-year period, 86%
(106,000 patients) of the total affected population is slated to have
access to ART by 2016 nationwide [personal communication,
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National AIDS Program]. To reach this important goal, the
number of patients receiving treatment in the public sector need to
be increased to 64,182 people, representing 61% of all patients on
ART in Myanmar.
Importance of retention in ART programs
As antiretroviral treatment becomes more readily available [2],
the next major challenge for the National HIV Control program
and the public sector will be to deliver high quality care [4]. In
addition to viral load suppression which remains the key marker of
treatment success, several other indicators have been used to
measure the quality of HIV programs [5–7]. While retention in
care of HIV-infected patients has been shown to reflect individual
treatment success [8,9], suboptimal retention is directly associated
with negative outcomes including longer time to viral suppression
[10], treatment failure and increased mortality [7,8,11,12]. Factors
associated with attrition (defined as the occurrence of death or loss
to follow up) have been described previously [13–27]; the most
common determinants include a late presentation to ART clinics,
and a poor nutritional status at baseline.
Previous studies in Myanmar
Determinants of treatment outcomes have been documented
within the private sector in an ART cohort administered by
Me´decins Sans Frontie`res (MSF)-Holland in Myanmar; in this
study the reported retention in care at 60 months reached 72%
[95% CI: 70–74] [25]. However, neither the retention rates nor
the determinants for attrition have been documented in the public
sector. Therefore, the primary objectives in this study are to
estimate the retention rates in a large ART program within the
public sector in Myanmar, and to determine risk factors for
attrition within this setting.
Methods
Ethics statement
Oral inform consent was obtained from all patients enrolled in
the cohort; written informed consent was not collected as it was
inadvisable to collect written documentation during the time of the
military regime in Myanmar. The oral consent was obtained by
marking a tick-box on the patient case form at enrollment after full
discussion with a trained peer counselor, and kept in the patient’s
file. The protocol was approved by the Ethical Advisory Group
(EAG) committee of the International Union Against Tuberculosis
and Lung Disease (hereafter ‘‘The Union’’) (EAG number 4/14).
All data were treated confidentially and stored as anonymized
data. Biological assays were performed as part of routine follow up
and all tests results were anonymized.
Setting
The Union has been implementing an Integrated HIV Care
(IHC) program within the public sector in collaboration with the
Department of Health, the National TB Program (NTP) and the
National AIDS Program (NAP) since 2005. Initially, it was
implemented at a single ART clinic in Mandalay. From that
starting point, there was a steady expansion of the program so that
by mid-2013, more than 15,000 patients were receiving ART in a
total of 14 ART centers and 12 ART decentralized sites in 6
regions. The entry points for enrollment in this IHC program
include TB clinics, pre-ART clinics run by the NAP, antenatal
clinics, and hospitals located in the project area. The IHC
program also accepts patients referred from other ART programs.
There are no geographical limitations for enrollment in the IHC
program (i.e. patients from the entire country have access to the
program).
After enrolment, patients went through a standardized process
including registration (allocation of a unique IHC code), baseline
clinical assessment and laboratory testing, confirmation of
eligibility by a selection committee and ART adherence counsel-
ing before ART initiation. Once patients are ‘‘stabilized’’,
generally 6 to 12 months after ART initiation at district or
tertiary hospitals, they are transferred out to the nearest
decentralization sites for chronic HIV care. Staff of the Ministry
of Health provides clinical care for ART initiation and follow- up.
The Union provides support including additional human resourc-
es (medical doctors, laboratory technicians …) comprehensive
laboratory investigations (CD4, viral load testing since 2012, and
other biochemical tests), drug procurement and supply manage-
ment, data entry, and program monitoring. Self-management
support from the People Living with HIV and AIDS (PLHA)
network are deployed in all ART sites and were actively involved
in the triage and registration, adherence counseling, and defaulter
tracing. They also play an important role in providing financial
assistance and social support for patients in distress.
The IHC program follows the national guideline for ART
initiation, and uses AZT/3TC or D4T/3TC plus an NNRTI as
first-line regimen, and protease inhibitor based regimens for
second line treatment. In 2013, the national guidelines were
updated to WHO recommendations and adopted TDF/3TC
(FTC) as the preferred reverse transcriptase inhibitors. TB/HIV
collaborative programs have been well established, and there is a
cross-referral system between TB clinics and ART clinics for
patients diagnosed at either of these sites. The enrolled patients
also get support for necessary drugs for treatment of opportunistic
infections (OI) and for required investigations if they are admitted
to the hospital.
Study design and population
We retrospectively analyzed a total of 10,413 patients who were
enrolled in our program between June 2005 and October 2011
and were followed up until April 2012 when censoring for this
analysis occurred. After removing patients with data inconsisten-
cies a total of 10,223 patients were considered for the 5-year
cumulative survival analysis. For the logistic regression and
survival analyses, patients with missing covariate data (primarily
CD4 at initiation) were removed, leaving a final total of 5,718
patients for estimation of risk factors for attrition (Figure 1). The
demographics of the full population and those with missing data
are compared in table S1 in File S1. The profile of both groups is
broadly similar; those with missing information were however less
likely to receive a TB treatment at the time of ART initiation, but
they were also more frequently reported with a previous ART
history. This difference is largely due to the fact that the program
absorbed an existing cohort of non-TB HIV-infected patients on
ART, and that CD4 testing was only introduced in June 2006,
while the program started one year earlier.
Definitions for primary outcomes
The primary outcome of this study was attrition, which included
death (all-cause) and loss to follow-up (LTF). Loss to follow-up was
defined as patients who did not return to clinic within three
months from their last scheduled appointment and who could not
be traced by the PLHA network. A system was in place to extract
the patient cohort code if they failed to come to the clinic and to
allow the PLHA network to trace the patients back within two
weeks. A small number of patients have been classified as LTF
after referral to non-IHC ART clinics, as we are unable to
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investigate the continuum of care for these patients. The primary
survival outcome was defined as those patients who were both
alive and still in active follow-up at the end of April 2012. Survival
time was measured from date of enrollment to date of death, last
recorded clinical visit, or study censoring date.
Data recording and storage
Routine patient medical data are recorded on paper forms by
attending clinicians and Union staff. These forms are computer-
ized in a password-protected database. All patient information was
entered into the database using a unique coding system and the
database is accessible only to data team members. We will make
freely available any materials and data described in this
publication that may be reasonably requested for the purpose of
academic, non-commercial research.
Statistical analysis
In this analysis, the models for attrition utilized recommenda-
tions for low-income settings which include CD4 count at baseline,
sex, age, ART regimen (NNRTI vs. PI-based) and clinical stage
(WHO stage I/II vs. III/IV) as independent predictors [28,29].
Both multivariate logistic regression and survival models were
utilized to assess risk factors for attrition.
We included in the multivariate models all variables associated
with attrition from the univariate analysis (at p,0.20 level). Age
was grouped as 18–30, 31–40, 41–50 and 51–60+ years; baseline
CD4 cell count was dichotomized using the standard clinical cut-
off of 100 cells per mm3 for HIV to AIDS progression
[14,15,18,20,25]. Both the Akaike and Bayesian Information
Criteria (AIC/BIC) were used to assess model parsimony.
Confounding was also assessed: case-control tabulation and
bivariate regression analyses were used to examine potential
interactions (defined as 15% change in coefficient of the referent
variable), and residual plots were examined for all multivariate
models.
For both analyses the predictors examined were: patient
characteristics (age, literacy, sex and alcohol consumption), and
baseline clinical and laboratory markers (BMI, WHO staging, type
of ART regimen, TB diagnosis and Cotrimoxazole prophylactic
treatment, CD4 cell count, anaemia, elevated liver transaminase
(ALT), prior OIs, and TB, hepatitis B and C serological status).
Proportion surviving was calculated using Kaplan-Meir meth-
ods; preliminary survival models used Cox proportional hazard
methods. Due to extensive proportional hazard violations in
multiple variables (anaemia, low BMI, and CD4,100 at
enrollment), Royston-Parmer flexible parametric survival models
were used [30]. These alternatives to standard Cox models add in
splines to directly model the underlying hazard functions, and
allow more comprehensive modeling and predictions.
Data management, exploratory data analyses and logistic
regressions models were fit using the software R 2.15; survival
analyses were performed using Stata 12.1, (College Station,
Texas); all tests were two-tailed with a=0.95.
Management of missing variables
A comprehensive sensitivity analysis of the missing variables was
performed and complete case analysis was performed for
estimation of risk factors for attrition. The characteristics of the
omitted and complete cases were similar with the exception of two
variables- those with missing data were more likely to have a
history of ART and less likely to have tuberculosis at baseline. As
such, we are unable to assume the data are missing completely at
random, which may introduce some bias in the estimates.
Our sensitivity analyses had two components. The first used
simulated data, whereby data were randomly generated for
missing values to assess the potential impact of ‘worst-case’
scenarios. The simulated data for each missing variable was
Figure 1. CONSORT diagram for analysis, with a total number of enrolled patients, number of patients for survival analysis and
number of patients to estimate risk factors for attrition.
doi:10.1371/journal.pone.0108615.g001
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assigned to one category and then used to compute adjusted odds
ratios; this process was then repeated, and re-run with the opposite
(for example, if the first set simulated a ‘male’ for all missing
values, then the second set this was reversed, with all missing data
coded as a ‘female’). The resulting sets of adjusted odds ratios were
then compared.
To complement this analysis, the univariate odds ratios for the
primary outcome were also compared between full case data and
those with missing data (table S2 in File S1).
Results
Baseline Characteristics
The mean (6SD) for age was 36 (68) years, and 61% of
patients were male among a total of 10,413 patients. The
demographic characteristics of study population at baseline such
as age, sex, literacy, use of alcohol and HIV risk factors are shown
in table 1. Clinical baseline characteristics (prior history of ART,
WHO clinical Stage at ART initiation, CD4 at baseline,
haemoglobin at baseline, HBV and HCV Status at baseline,
BMI (baseline), type of ART regimen at baseline, Cotrimoxazole
preventive therapy at baseline, tuberculosis treatment at ART
initiation) are summarized in tables 2 and 3. Twenty four percent
of patients had a prior ART history, 74% were classified as WHO
stage III or IV and 46% had CD4 less than 100 cells/ml at ART
initiation.
Retention Rate
The cumulative outcomes were death 909 (9%), loss to follow up
750 (7%) and in active follow up 8,564 (84%) for the cohort used
for survival analysis (n = 10,223) with the median follow up
duration of 13.7 months (interquartile range [IQR] 5.5–28.7). The
corresponding retention rates and 95% CI of participants were 12
months (86; 85–87); 24 months (82; 81–83); 36 months (80; 79–
81); 48 months (77; 76–78); 60 months (74; 73–76) (figure 2).
Incidence density for attrition
Among 10,223 patients, 1,542 attrition [death or LTF] events
occurred over 17,524 person-years at risk, with an annual
incidence density of 8.8% (95% CI: 8.4–9.3) in our study. In
comparison, 1,061 attrition [death or LTF] events occurred
among 5,963 patients over 14,854 person years at risk with an
incident density of 7.0% (95% CI: 6.7 to 7.6) per year in the
private setting [25] (Table 4). However, we found that the
cumulative attrition (death+ default) rate in the very first
decentralized sites of IHC program was quite low (3%).
Risk Factors for Attrition
Two complementary analyses were performed to investigate risk
factors for attrition. The risk factors identified in logistic regression
analysis are shown in Table 5 as odds ratios for primary outcome
(death or loss-to-follow-up), and those identified in survival models
are shown in Table 6 as hazard ratios from multivariate analysis.
Determinants for Attrition by Logistic Regression
After adjustment in a multivariate model, the significant factors
identified were male sex [OR 1.4, 95% CI: 1.21–1.65]; illiteracy
[OR 1.47, 95% CI: 1.21–1.79]; prior history of ART [OR 0.73,
95% CI: 0.58–0.90]; WHO stage III or IV at baseline [OR 2.36,
95% CI: 1.90–2.94]; BMI,18.5 kg/m2 [OR 1.97, 95% CI: 1.71–
2.26]; CD4 less than 100 cells/ml at baseline [OR 1.47, 95% CI:
1.29–1.69]; anaemia at baseline [OR 1.67, 95% CI: 1.36–2.05]
and protease inhibitor based regimen [OR 4.35, 95% CI: 1.22–
15.49].
Determinants for Attrition by Parametric Survival Model
In the adjusted multivariate flexible parametric model, the
independent risk factors for attrition were: BMI,18.5 [HR 2.06,
95% CI: 1.76 to 2.40]; WHO stage III or IV at baseline [HR 2.01,
95% CI: 1.58 to 2.57]; anaemia at baseline [HR 1.80, 95% CI:
1.41 to 2.30], and baseline CD4 count ,100 cells/ml [HR 1.74,
95% CI: 1.50 to 2.01].
Two factors showed marginally significant increased hazard:
Cotrimoxazole treatment at baseline [HR 1.58, 95% CI: 1.10 to
2.25], and male gender [HR 1.37, 95% CI: 1.17 to 1.61].
Several factors showed a protective effect: previous ART at
baseline [HR 0.61, 95% CI: 0.42 to 0.86], literacy [HR 0.81, 95%
CI: 0.67 to 0.98] and TB treatment at baseline [HR 0.82, 95% CI:
0.71 to 0.94] (figure 3).
Analysis of missing data
The comparison of baseline demographics between full-data
cases and those with missing data are presented in table S1 in File
S1. All population characteristics are broadly similar with the
exceptions of a more frequent ART history and a lower proportion
of TB treatment at ART initiation in the group with missing data.
The comparison of the univariate odds ratios between cases
with full data and those with missing values (table S2 in File S1),
shows small differences in the point estimates between the two
groups, but no changes in the substantive conclusions based upon
the 95% CIs, with the exception of ‘‘PI-based regimen’’ which
becomes not significant in the missing data group (2.39, 95% CI:
0.8 to 7.15) and ‘‘not literate’’ where it becomes not significant in
the missing data group (1.15, 95% CI: 0.84 to 1.58).
Finally, the comparison of the multivariate odds ratios with the
simulated data found only minor differences in point estimates and
confidence intervals of the odds ratios, with the exception of the
history of ART, where the odds ratio crosses one in the cases with
simulated data (table S3 in File S1).
Discussion
Several studies conducted in low and middle income countries
have provided estimates for retention in HIV cohorts; however,
most of these studies analyzed a limited number of patients and
described only short- to medium-term retention.
Retention in other Asian cohorts
Studies from Cambodia documented the outcomes of ART for
short and medium term; the incidence of mortality was 9.1 per 100
person-years which is similar to international standards [31], the
two year retention estimate was 85.5% both in a cohort of 416
patients treated in a Me´decins Sans Frontie`res/Ministry of Health
program [32], and in a larger cohort of the Sihanouk Hospital
Center of HOPE, Phnom Penh [13]. The national program of
Vietnam reported retention rates after 6, 12, 24, and 36 months as
88.4% [95% CI: 86.8–89.9], 84.0% [95% CI: 81.8–86.0], 78.8%
[95% CI: 75.7–81.6], and 74.6% [95% CI: 69.6–79.0] [27]. In
Thailand the survival rates among HIV-TB co-infected patients
were 96.1%, 94% and 87.7% at 12, 24 and 36 months,
respectively [33]. The retention at 12 month and 24 month of
the Chinese National Free Antiretroviral Treatment Program was
92% and 84% [34] and the 12-month retention among eight Asia
Pacific countries ranged from 65% to 88% [35].
The National AIDS Program in Myanmar reported a national
retention rate of 87% at 12 months after ART initiation for those
who received ART in 2010 [1]. The IHC program retention rate
at 5 years was 74% [95% CI: 73–76], which is similar to the one
reported by MSF Holland in its private sector cohort (72% [95%
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CI: 70–74]) [25]. However, there was a significant difference in
the incidence density for attrition between the cohorts: 7.1% [95%
CI: 6.7–7.6] per year in MSF versus 8.8% [95% CI: 8.4–9.3] per
year in IHC program.
Possible explanations for these differences include the patient to
provider ratio, and the corresponding time within the clinic, which
can be better in a private setting with greater resources relative to
the public sector. While it is extremely challenging to have reliable
conclusions on trends in retention rates and to produce consistent
nationwide data from many resource-limited countries [2],
comparing and combining the results of the two largest cohorts
in Myanmar may permit the national AIDS program to track
outcomes of ART programs as national figures.
Variations in program definitions
Currently, there is no consensus on how to best assess program
retention [9]; although a study that analyzed 111 facilities
worldwide suggested defining failure as more than 180 days from
the last scheduled appointment [36]. Other methods that have
been used include counting missed visits [37], appointment
adherence [8] and gaps in care; and the number of gaps within
6, 9, or 12-month periods [9]. Various cohorts have reported
various retention rates including 35% in Cameroon [24], 74.6% in
Vietnam [27] and 82% in the MSF program in Myanmar [25] at
36 month follow up.
Consideration of missing data
There is considerable debate as to the optimal strategy to handle
missing data in cohort studies, and no method is optimal under all
circumstances [38].
In this analysis we have focused on cases with full available data
(complete case data), to maximize the comparability to studies in
similar settings that have appeared in the literature. While this has
the potential for introducing biases if the nature of missing data
has an influence on the primary outcome, the multiple sets of
complementary sensitivity analyses we have performed suggest
these effects are likely small. Moreover, the demographics (age,
sex, etc.) of the patients with missing data are remarkably similar
to the included patients, with two exceptions. A higher proportion
of patients with missing data have history of prior ART, while a
lower proportion have TB treatment at ART initiation. The broad
agreement of our results with prior studies suggests that any biases
in our data analysis are likely minor.
Attrition
Many factors have been linked to attrition in various settings,
including the type of ART regimen at initiation [39], time to start
of ART [16,33], nutritional deficiency and anaemia
[13,18,20,22,25], higher education [40] and strategic placing of
ART service delivery points [24]. By focusing on modifiable
factors in this cohort analysis, we aimed to provide an evidence
base to inform policy makers on how to improve outcomes in ART
programs implemented in Myanmar and SE Asia.
Comparison with a private sector cohort in Myanmar [25]
Our findings are similar to the results of the MSF cohort
analysis. In The MSF cohort, high WHO staging, low BMI, male
sex and age were found to be independent risk factors for attrition.
Our study did not find a strong impact of age, but also identified
that a low CD4 count and anaemia were risk factors for attrition;
conversely, TB treatment at ART initiation, ART history and
literacy were found to be predictors for the retention in care. The
observed differences are likely to be due to differences in program
structure, and potentially to some differences between the study
populations.
CD4
One of the main risk factors for attrition is low CD4 count at
enrollment; this is a common feature which has been found in
many other cohort studies [13–23]. Our study found an adjusted
hazard ratio for attrition of 1.74 (95% CI: 1.50–2.01), much
higher in patients with low CD4 at ART initiation. These finding
reinforce the crucial importance of early HIV diagnosis and timely
initiation of ART in the broader perspective of increasing survival
rates [17,21].
However, pooled data from 13 research cohorts from five sub-
Saharan African (Benin, Burkina Faso, Cameroon, Cote d’Ivoire
and Senegal) and two Asian (Cambodia and Laos) countries
reported a lower survival not only in those patients with low CD4
but also for patients with a high CD4 count [19], which is likely
due to the presence of co-morbidities.
Figure 2. Unadjusted Kaplan-Meier survival curves, full cohort
(N=10,223).
doi:10.1371/journal.pone.0108615.g002
Table 4. Attrition Rate at 36-month follow up of the cohort in the public sector comparing with MSF (H) cohort.
Service Delivery PointParticipants (N)
Attrition Cases (N) [death+LTF]
during 36 months of follow-up
Person years at risk
(to 36 months)
Attrition Rate (%)
Per Year 95% Confidence Interval
Private [MSF] 5,963 1,061 14,854 7% (6.7–7.6) %
Public [The Union +DOH]10,223 1,542 17,524 8.8% (8.4–9.3) %
N: Number; LTF: Loss to follow up; MSF (H): Me´decins Sans Frontie`res (Holland); DOH: Department of Health.
doi:10.1371/journal.pone.0108615.t004
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BMI, WHO staging and anaemia
Several studies exploring HIV attrition found independent
associations between attrition and low BMI [13,18,20,25], WHO
staging III/IV [16,18,20,21,25], and anaemia [13,18,20,22]. We
found similar associations in our cohort, and these factors are even
stronger predictors of attrition than low CD4 count. Our findings
support the prioritization of nutritional support and of appropriate
management of anaemia as key interventions within the scope of
Table 5. Prevalence percentages and odds ratios for primary outcome (death or loss-to-follow-up) from the logistic regression
analysis.
Bivariate Analysis Multivariate Analysis
Alive and still in
follow-up (N=8615)
Negative outcomes: death,
lost to follow up (N=1798) OR (95% C.I.) OR (95% C.I). p-value
Age: Mean (SD) 35.9 (8.0) 36.0 (8.5) - - 0.980
Sex: male 59.1 69.2 1.55 (1.39–1.73) 1.42 (1.21–1.65) ,0.001
Alcoholism: yes 26.0 30.5 1.25 (1.11–1.40) 0.98 (0.84–1.15) 0.804
Literate 90.5 88.1 0.78 (0.66–0.91) 0.68 (0.56–0.83) ,0.001
Prior history of ART 25.1 18.6 0.68 (0.60–0.78) 0.73 (0.58–0.90) 0.004
WHO Stage III/IV at baseline 71.4 87.5 2.81 (2.43–3.26) 2.36 (1.90–2.94) ,0.001
Underweight (BMI ,18.5) 44.7 68.3 2.66 (2.37–3.00) 1.97 (1.71–2.26) ,0.001
CD4 at baseline ,100 42.9 62.6 2.23 (1.99–2.48) 1.47 (1.29–1.69) ,0.001
Anaemia at baseline 77.2 90.1 2.69 (2.27–3.19) 1.67 (1.36–2.05) ,0.001
Tuberculosis treatment at baseline 34.0 45.5 1.62 (1.46–1.79) 0.90 (0.78–1.04) 0.140
PI base regimen 0.2 0.6 3.26 (1.46–7.28) 4.35 (1.22–15.49) 0.023
Cotrimoxazole preventive therapy at
baseline
91.3 93.5 1.37 (1.12–1.67) 1.12 (0.84–1.50) 0.455
OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; SD: Standard deviation; PI: Protease inhibitor; Anaemia: Haemoglobin concentration ,12 g/dL in women
and ,13 g/dL in men.
doi:10.1371/journal.pone.0108615.t005
Table 6. Flexible parametric survival model of potential determinants for attrition among study population (N= 5,718).
Cox Univariate Analysis Flexible Parametric Survival Model
HR, 95% C.I. HR, 95% C.I. p-value
Age 18–30 reference reference -
31–40 0.96 (0.85–1.07) 0.90 (0.77–1.06) 0.201
41–50 1.03 (0.89–1.20) 0.93 (0.76–1.13 0.466
51–60 + 1.31 (1.06–1.61) 1.21 (0.90–1.64) 0.194
Enrollment group Early reference reference -
Later 1.27 (1.14–1.42) 1.09 (0.94–1.26) 0.250
Sex: male 1.43 (1.29–1.59) 1.37 (1.17–1.61) ,0.001
Alcoholism: yes 1.26 (1.13–1.40) 1.05 (0.90–1.22) 0.542
Literate 0.83 (0.72–0.97) 0.81 (0.67–0.98) 0.031
Prior history of ART 0.52 (0.46–0.58) 0.61 (0.42–0.86) 0.005
Cotrimoxazole at baseline 1.34 (1.07–1.70) 1.58 (1.10–2.25) 0.011
WHO Stage III/IV at baseline 2.35 (2.00–2.76) 2.01 (1.58–2.57) ,0.001
Underweight (BMI,18.5) at baseline 2.55 (2.27–2.85) 2.06 (1.76–2.40) ,0.001
CD4 at baseline ,100 2.73 (2.30–3.24) 1.74 (1.50–2.01) ,0.001
Anaemia at baseline 2.27 (1.88–2.75) 1.80 (1.41–2.30) ,0.001
Tuberculosis treatment at baseline 0.65 (0.59–0.72) 0.82 (0.71–0.94) 0.005
PI regimen at baseline 2.03 (1.01–4.07) (ns #) 0.989
CI: Confidence interval; BMI: Body mass index; PI: Protease inhibitor; WHO definition of Anaemia: Haemoglobin concentration ,12 g/dL in women and ,13 g/dL in
men.
#- not significant in univariate models.
Note: Early enrolment (1 Sep 2005 to 31 Dec 2009), and Late enrolment (1 Jan 2010 to 20 Oct 2011).
doi:10.1371/journal.pone.0108615.t006
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the comprehensive care activities proposed in ART clinics in
Myanmar. These results also suggest that insufficient nutrition is
potentially an important risk factor for attrition in the study
population. Further research is needed to more fully explore this
association within Myanmar.
Sex and Cotrimoxazole preventive therapy
Although the association is weak, male gender is an independent
risk factor for attrition. This is in line with the results from other
studies [13,15,23–25].
In contrast to a report from Thailand [26], we have found that
cotrimoxazole prophylactic prescription is a risk factor for attrition
by parametric survival models. This association is unsurprising as
all patients with low CD4 or high WHO staging (both conditions
known as strong predictors for attrition), are also treated with
cotrimoxazole. This association, however, persisted in the
multivariate analysis. This association could be an artifact; the
lower range of the confidence interval [HR=1.58 (95% CI: 1.10
to 2.25)], suggests only a marginal 10% increase in risk of event.
This result was not found in logistic regression and may represent
a spurious association.
Comparison of first and second line regimens
A review of 18 cohorts in Europe and North America concluded
that patients on protease inhibitor had higher probability of
treatment interruption or modification; this review also highlight-
ed that those patients receiving tenofovir/emtricitabine based
regimens had lower probability of treatment substitutions com-
pared to non-standard regimens [41]. In our cohort, the odds for
attrition are higher for those patients receiving protease inhibitor
based regimens [OR 4.35, (95% CI: 1.22 to 15.49)] when
compared with patients on an NNRTI based regimen. While the
number of patients on PI included in the analysis is limited, it is
vital to investigate further whether this increased risk is due to
delays in referral from non-IHC sites, or instead to the regimen
itself in this particular setting.
Like other resource-limited settings, IHC programs in Myan-
mar used d4T as the main NRTI (67%) followed by AZT (31.2%)
and TDF (2.3%) for ART initiation. A recent study from South
Africa evaluated the effectiveness of TDF and reported that the
adjusted hazard ratio for loss-from-care, when compared to TDF,
was 1.5 (95% CI: 1.1–1.9) for d4T and 1.2 (95% CI: 1.1–1.4) for
AZT [39]. In our study, only a small number of patients were
treated with TDF, and a similar association was not found.
However, the retention rate is higher in the unadjusted KM
analysis for those on AZT when compared with patient receiving
d4T-based regimens (p,0.0001), (Figure 4). As the effectiveness of
modern cART regimens becomes widely documented it is
worthwhile to recommend using those regimens whenever possible
in ART programs [34]. In Myanmar, national antiretroviral
treatment guidelines have been modified in mid-2013 to take into
account the latest WHO recommendations and include the
adoption of TDF/3TC as the preferred option for ART initiation.
Figure 3. Adjusted hazard ratios from flexible parametric survival analysis (N=5,718).
doi:10.1371/journal.pone.0108615.g003
Figure 4. Unadjusted Kaplan-Meier curves, by first-line ART
regimen.
doi:10.1371/journal.pone.0108615.g004
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Attrition and TB co-infected patients, previous ART and
Literacy
The protective factors for attrition include the administration of
a TB treatment at ART initiation and a prior ART history
(Figure 5); the better retention in care observed in these two
groups can be explained by the more intensive counseling received
by these patients in the TB clinics and by earlier ART care
providers. In our cohort, 90% of study participants are literate
and, not surprisingly, have a higher retention when compared to
those with limited literacy. Increased educational attainment has
been shown to have a strong positive impact on clinical outcomes
[40] and more globally in cohort retention.
Free of charge medical care, adherence support and
defaulter tracing
A cluster randomized control trial in Vietnam reported that
there was no significant difference in mortality rate between
groups who received enhanced adherence versus a control groups
without intervention [18]. A study from an ART clinic in
Cameroon where patients had to pay for ART, found no
difference in retention rates between before and after ART cost
reduction [58%, 47% and 35% at 12, 24 and 36 months
respectively] [24]. These findings highlight the importance of
defaulter tracing in programs apart from the cost of ART.
Implementation of support group activities in all project sites, peer
involvement in defaulter tracing, and free access to all services are
important aspects of the program in Myanmar that may explain
these successes.
The modifiable risk factors for attrition we found could motivate
attending clinicians to provide more comprehensive care to
achieve both increased individual benefit and greater impact at
the population level.
ART site and decentralized sites
We found that the attrition remains quite low (3%) in the initial
decentralized sites. Patients might have less constraint to come to
these sites and better efforts might have been allocated to
‘‘stabilize’’ these patients (including the treatment of co-morbid-
ities) before the transfer.
Strength and limitations
One of the main strengths of this study is the sample size, which
allowed us to investigate the retention in care and the risk factors
for attrition in a large cohort of patients followed in the public
sector in Myanmar. However, there are also some limitations.
First, it should be acknowledged that a significant number of
patients with missing data were excluded from the analysis,
potentially introducing bias. Secondly, the study assessed a limited
number of socio-demographic factors; we were not able to include
in our analysis other important parameters such as the distance
between the patients’ residence and the service delivery point [24]
and the absorption capacity of the ART clinics [15]. Our study
also mainly included patients who had already started ART while
it would have also been important to try analyzing attrition before
ART initiation [42]. We were also not able to analyze the
biological markers after ART initiation [43]. Finally we were not
able to capture any secular changes in standards of care and
systematic changes within the health sector in Myanmar.
Conclusion
Our study, conducted in a resource-limited setting, provides
evidence about the quality and the effectiveness of a large ART
program from the public sector in Myanmar. It also advocate for
the feasibility of the long-term retention of a large cohort of
patients on ART within an Integrated HIV Care program in
Myanmar. Our result suggests that key improvements for future
programs are early diagnosis of HIV and initiation of ART,
comprehensive nutritional support to increase BMI to normal
levels, and targeting those patients with low CD4 count and/or
haemoglobin for intensive investigation and clinical management.
Finally, a comprehensive study of patients in second-line therapy
settings would be an important next step in addressing these
programs gaps.
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